biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Inherited Retinal Diseases: From Pathomolecular Mechanisms to Therapeutic Strategies

Guest Editor:

Dr. José Martín-Nieto
Departamento de Fisiología, Genética y Microbiología, Facultad de Ciencias, Universidad de Alicante, 03080 Alicante, Spain

Deadline for manuscript submissions:
31 January 2025

Message from the Guest Editor

Inherited retinal diseases (IRDs) constitute a large group of genetically and clinically heterogeneous disorders characterized by photoreceptor degeneration or dysfunction, with the ensuing degeneration of the retina ultimately leading to the loss of visual function and legal blindness. In this context, the accurate genotyping of individuals with IRDs is essential for patient management and the identification of suitable candidates for gene therapies.

This *Biomedicines* Special Issue invites contributions dealing with the identification of new genes and variants associated with these ocular disorders, in addition to the application of genetic and genomic technologies to their personalized diagnostics. In addition, this Special Issue will welcome articles that shed light on the molecular and cellular mechanisms of genetic retinal pathogenesis, including the functions of morbid genes and their protein products in retinal health and disease. Finally, the latest therapies (pharmacological, gene-specific, stem-cell-based, etc.) for IRDs that are under investigation and development, including clinical trials, will also be covered.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI